retatrutide phase 2 nejm 2023 percent weight loss 48 weeks 2023年度回顧】 Notable Articles of Day 3: Triple–Hormone-Receptor Agonist for Obesity — A Trial. N Engl J Med 2023; 389:514-526. 製圖：Sardinosis Retatrutide (not yet approved in

For example, phentermine can cause a rapid or irregular heart rate, high blood pressure, headache, and insomnia

GLP-1 RAs are very effective at lowering blood sugar levels both after meals and during fasting

In a clinical trial of the Wegovy pill in people without diabetes, people taking a 25 mg dose lost about 6% of their body weight in three months

From Eli Lilly, also the manufacturer of Mounjaro and Zepbound, Retatrutide is a GLP-1 (glucagon-like peptide-1) receptor agonist that also works on the hormones GIP (glucose-dependent insulinotropic polypeptide) and glucogen

Managing PCOS and Weight PCOS causes weight gain and difficulty losing weight due to insulin resistance